A new trial update for vasopressin was posted on October 2, 2026. The study, titled "Intracervical Vasopressin," is registered under identifier NCT07102615. It is listed as a Phase 4 trial, meaning it involves further study of an already approved compound. According to the posted record, the trial status is currently "recruiting," indicating that enrollment of participants is actively underway.
No results, outcomes, or efficacy data are included in this update. The record only confirms the trial's title, phase, and current recruitment status as of the listed date. No information about the number of participants, specific endpoints, or expected completion date was provided in this event.
Vasopressin itself carries an approved regulatory status. This particular trial update does not change that status, and it does not provide any new safety or effectiveness information about the compound. Readers interested in the design or purpose of this study can consult the official ClinicalTrials.gov listing for further details.
For more background on this compound, including its approved uses and general profile, readers can refer to the compound overview.